EDX Medical Expands UK Access to BC95 Bowel Cancer Biomarker Test Targeting Early Detection

BC95 Test Composition and Clinical Basis

The BC95 test integrates three components to comprehensively address bowel cancer screening and risk evaluation. Central to the service is the EarlyTectae epigenetic biomarker assay, which detects abnormal methylation of the SDC2 gene promoter—a molecular alteration commonly present in early colorectal cancer tissue. Unlike conventional faecal immunochemical tests, this method identifies molecular cancer changes at earlier disease stages.

The second component offers an extensive hereditary genetic risk panel, enabling identification of individuals with familial predisposition to bowel cancer. The third element is a faecal haemoglobin reference test consistent with NHS screening protocols. This multi-tiered approach allows clinicians to evaluate patients’ molecular biomarker status, genetic risk, and traditional haemoglobin markers in a single test session.

Clinical Outcomes and Early Detection Strength

EDX Medical’s clinical evaluation involving 1,124 asymptomatic patients (1.8% disease incidence) demonstrated an overall 95% sensitivity across colorectal cancer stages 1 to 4. Notably, early-stage cancers (stages 0 to 2) were detected with 89.1% sensitivity, addressing a critical challenge in bowel cancer management where late diagnosis limits treatment options and survival rates.

The test also identified advanced adenomatous polyps with 58.1% sensitivity, supporting its use in monitoring high-risk patients due to hereditary or lifestyle factors. The announcement does not disclose specificity, negative predictive value, or comparative performance against other UK bowel cancer screening tests. The study’s population size and design align with previously disclosed data.

Exclusive UK Partnership with Genomictree Ltd

EDX Medical secured exclusive UK rights to distribute Genomictree Ltd’s EarlyTectae epigenetic test, which measures SDC2 gene methylation. This exclusive agreement positions EDX Medical as the sole UK provider of this highly sensitive colorectal cancer biomarker test, described as "the most sensitive and accurate epigenetic biomarker test for colorectal cancer currently available in the UK," reflecting the company’s assessment rather than independent validation.

This partnership exemplifies a common diagnostics industry model where established market players collaborate with technology innovators to commercialize novel assays regionally. EDX Medical leverages its UK healthcare network and clinical relationships to distribute a validated biomarker test without incurring assay development costs.

Company Operations and Leadership

EDX Medical Group plc operates facilities in Cambridge and Oxford, UK, and is listed on the AIM market under ticker EDX. Founded by Professor Sir Christopher Evans, a seasoned medical entrepreneur, alongside CEO Dr Mike Hudson, the company focuses on translating clinical insights into cost-effective diagnostic solutions combining advanced biology and digital platforms. EDX Medical serves doctors, hospitals, and insurers, supported by strategic partnerships including Thermo Fisher EMEA Ltd, enhancing assay development, quality assurance, and distribution.

UK Cancer Diagnostics Market Expansion and Strategic Positioning

The UK cancer diagnostics market is experiencing rapid growth with significant value increases forecasted. CEO Dr Mike Hudson highlighted consumables as "the fastest growing segment" within this market, indicating strong commercial opportunity for consumable-based biomarker tests like BC95.

With over 46,000 annual bowel cancer diagnoses and approximately 17,700 deaths in the UK, bowel cancer remains a major clinical priority. Increasing incidence among younger patients further underscores the need for early detection. Preliminary clinical evaluation revealed particularly high demand for the early-detection biomarker component among healthcare professionals prior to full launch.

Healthcare Professional Feedback and Market Reception

During limited clinical availability, BC95 was offered to select clinicians to gather feedback and assess demand. The company reported "particularly strong" interest in the early-detection test component, supporting the transition to full UK availability.

Professor Sir Chris Evans stated, "Early indications from healthcare professionals show strong interest in the early detection element of the testing service, and we believe the combination of complementary tests in BC95 is unique in the UK." This reflects EDX Medical’s view of BC95’s novel integrated architecture within the UK market, although no direct competitor comparisons were provided.

Management Insights on Detection and Patient Impact

Dr Mike Hudson emphasized the clinical need for earlier bowel cancer detection: "Late detection has long limited treatment options and survival, especially as bowel cancer increasingly affects younger patients." He positioned BC95 as addressing this detection challenge and aligning with growth in cancer diagnostics demand.

Management views the cancer diagnostics sector as a "key growth market," focusing on expanding testing volumes through consumable-based solutions rather than competing solely on price or novel diagnostic modalities.

Patient Advocacy and Public Health Perspective

Cancer advocate Charlotte Rutherford, diagnosed with stage 4 bowel cancer at 26 and now in remission, highlighted the importance of symptom awareness and early consultation: "Many people don’t recognize symptoms or delay seeking help. I encourage everyone to take control and not ignore warning signs." She stressed that early diagnosis dramatically improves treatment options and outcomes, praising innovative tests like BC95 for empowering proactive health management.

Her perspective underscores the patient-centered rationale for early-detection diagnostics, complementing clinical and commercial narratives.

AIM Listing and Capital Market Access

EDX Medical Group plc is listed on the AIM market (ticker EDX), providing access to public capital for growth initiatives including service expansion and product development. AIM caters to smaller, growth-oriented companies with distinct regulatory frameworks. The announcement does not disclose market capitalization, share price, or capital raising related to BC95.

The listing supports EDX Medical’s growth strategy within a regulated environment. The company’s primary facility is located in Cambridge, UK. Financial details related to BC95 development or commercialization were not provided.

Strategic Collaborations and Infrastructure

EDX Medical’s strategic partnerships extend operational capabilities beyond its UK facilities. Notably, Thermo Fisher EMEA Ltd, a global life sciences leader, supports assay supply, instrumentation, quality assurance, and distribution for BC95. Specific partnership terms were not disclosed.

This collaborative model aligns with diagnostics industry norms, emphasizing clinical market access and commercialization over full vertical integration.

Market Dynamics and Growth Drivers

The UK cancer diagnostics market is expanding due to increased testing volumes, adoption of advanced diagnostics, and enhanced reimbursement. Consumables represent the fastest-growing segment, reflecting demand for standalone test services.

With over 46,000 UK bowel cancer cases annually and rising incidence among younger patients, screening programs and early intervention are expected to grow. Globally, colorectal cancer ranks as the second leading cause of cancer death, emphasizing the need for diagnostic innovation.